

CORRECTION

Correction: *In Vitro* Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia

Kentaro Minagawa, Muhammad O. Jamil, Mustafa AL-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P. Erba, Lawrence S. Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi

The following information is missing from the Funding section: A.D. was supported by an American Cancer Society (ACS) New faculty Career Development Grant, and by a "Walter B. Frommeyer Jr. Fellowship in investigative medicine."

Reference

1. Minagawa K, Jamil MO, AL-Obaidi M, Pereboeva L, Salzman D, Erba HP, et al. (2016) *In Vitro* Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS ONE 11(12): e0166891. doi:[10.1371/journal.pone.0166891](https://doi.org/10.1371/journal.pone.0166891) PMID: [27907031](https://pubmed.ncbi.nlm.nih.gov/27907031/)



OPEN ACCESS

Citation: Minagawa K, Jamil MO, AL-Obaidi M, Pereboeva L, Salzman D, Erba HP, et al. (2017) Correction: *In Vitro* Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS ONE 12(2): e0172640. doi:[10.1371/journal.pone.0172640](https://doi.org/10.1371/journal.pone.0172640)

Published: February 15, 2017

Copyright: © 2017 Minagawa et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.